Baxter Q1 Edited

Robert Parkinson

.......I'd like to take a moment just to update you on a few key programs and some recent highlights. First, during the quarter, we submitted a Biologics License Application or BLA to the FDA [Food and Drug Administration] for the U.S. approval of TISSEEL Fibrin Sealant as a hemostatic agent in vascular surgery. This is an expansion beyond the current marketed indications and completes the necessary clinical requirements for a broad hemostasis label, which represents a very significant opportunity for our Regenerative Medicine business.

Robert Hombach

.....Sales in Regenerative Medicine, which includes our BioSurgery products totaled $140 million and increased 18% on both the reported basis and after adjusting for foreign currency. These results reflect solid growth, particularly for FLOSEAL, and a benefit of just over $10 million in incremental sales related to the Apatech [ApaTech Inc.] acquisition, which was completed at the end of the first quarter last year. Excluding ApaTech, sales gross for the category was in high single digits.

Entegrion Licenses Stasilon Bleeding Control Dressing to Beeken BioMedical

Research Triangle Park, NC-based life sciences development company focused on expanding the therapeutic potential of the human vascular system signs agreement with new Chicago-based medical device company to continue development and commercialization of FDA-cleared hemostatic dressing.
Research Triangle Park, NC (PRWEB) April 20, 2011
Entegrion, the life sciences development company focused on expanding the therapeutic potential of the human vascular system, announces it has licensed Stasilon® to the Chicago-based medical device company Beeken BioMedical. Stasilon® is an FDA-cleared, single-use hemostatic dressing applied externally with mechanical compression to temporarily control bleeding in lacerations, punctures, abrasions and incisions.
“Beeken BioMedical is committed to continue the development and commercialization of Stasilon®,” said Richard A. Kendall, President and CEO of newly formed Beeken BioMedical. “This novel medical device that extends across all of healthcare gives our company an immediate presence in the healthcare industry with opportunities to expand our sales and distribution model.”
“We selected Stasilon® as the company's initial investment for many reasons, including technology innovation and the fact that it is a low cost but effective alternative to current hemostatic devices in the market and a strategic fit to our global distribution model,” said Peter Beemsterboer, Chairman of Beeken BioMedical. “We look forward to having Entegrion as a strategic partner to further develop our product portfolio.”
Entegrion, which developed the hemostatic woven dressing in collaboration with researchers at the University of North Carolina, commented on the agreement. “We are pleased to partner with Beeken BioMedical in the introduction of Stasilon® to the surgical and wound care community. We are confident they have the experience, drive and imagination to successfully represent the technology, and, as importantly, identify additional unmet medical needs that can be addressed by future generations of products,” said Joseph DaCorta, Entegrion's Vice President and Chief Technology Officer. “They are the ideal partners for us.”
Beemsterboer and Kendall are the co-founders of Beeken BioMedical. The entrepreneurs have diverse and extensive backgrounds in developing multi-million-dollar businesses that introduce new technologies and services into healthcare and non-healthcare-related industries. The company has selected an experienced management team to continue the development and growth of the company.
Regulated as a medical device, Stasilon® addresses the immediate need to control bleeding surfaces by treating wounds caused by trauma with a novel dual-fiber hemostatic dressing. Beeken BioMedical will focus on the unique features of Stasilon® to continue to be among the first choice of hemostasis devices selected in surgery, wound care, emergency medicine, industrial and consumer care. Potential market opportunities range from hospitals, clinics, physician offices, long term and emergency care facilities, municipalities, veterinary clinics, and athletics to over-the-counter use by consumers